# GetRetatrutide.ca — Full Content Reference

> Evidence-based information about retatrutide (LY3437943) for Canadians. Bilingual (en-CA / fr-CA). Built with Astro v6 + Tailwind CSS v4. Last updated: May 2026.

---

## Site Overview

**Domain**: getretatrutide.ca
**Purpose**: Independent educational resource tracking retatrutide's clinical development, Canadian access pathways, safety data, and regulatory progress.
**Audience**: Canadians seeking accurate information about this investigational weight loss treatment — patients, healthcare providers, researchers.
**Editorial stance**: Not affiliated with any pharmaceutical company. No sponsored content. No medical advice. All factual claims linked to primary sources (NEJM, ClinicalTrials.gov, Health Canada, Lilly press releases).

---

## Page-by-Page Content Summary

### / (Homepage)
- Hero: Triple-agonist explanation, 3 CTAs (How it works / Clinical data / Access in Canada)
- Stat row: ~24% weight loss (Phase 2), 3 receptors targeted, Phase 3 status
- How retatrutide differs section: NEJM Phase 2 link, TRIUMPH-1 results (30.3%) update
- Comparison table: Retatrutide vs tirzepatide vs semaglutide with NCT links
- Canadian access pathways: Clinical trials, Health Canada SAP, future approval
- FAQ: 5 questions with schema.org markup

### /what-is-retatrutide/
- Triple-agonist mechanism: GIP, GLP-1, glucagon receptors explained
- Receptor-by-receptor breakdown (GLP-1 → satiety, GIP → metabolism, glucagon → energy expenditure)
- Synthetic peptide design: amino acid modifications, weekly dosing rationale
- Comparison table: 5 drugs (retatrutide, tirzepatide, semaglutide, liraglutide, orforglipron)
- Clinical timeline: Phase 1 → Phase 2 (NEJM 2023) → Phase 3 TRIUMPH with NCT links
- Distinction: pharmaceutical-grade vs unregulated research chemicals

### /clinical-trials/
- TRIUMPH program overview: 5 Phase 3 trials
- Phase 2 results detail: 338 participants, 24.2% weight loss, NEJM citation
- TRIUMPH-1 (NCT05929066): Obesity, results reported May 2026 — 30.3% weight loss
- TRIUMPH-2 (NCT05929079): Type 2 diabetes + obesity, expected May 2026
- TRIUMPH-3 / TRIUMPH-OUTCOMES (NCT06383390): CV outcomes, 22 Canadian sites, through 2029
- TRIUMPH-4 (NCT05931367): Knee OA, completed Nov 2025, 10 Canadian sites
- TRIUMPH-5 (NCT06260722): Head-to-head vs semaglutide, 12 Canadian sites, expected Aug 2026
- Canadian enrollment instructions

### /compare/
- Receptor targets comparison table (GIP, GLP-1, glucagon)
- Clinical trial results: Phase 2 (NEJM 2023), SURMOUNT-1 (NEJM 2022), STEP-1 (NEJM 2021) — all with DOI links
- Side effect profiles comparison
- Canadian availability: approved vs clinical trials only
- Cross-trial comparison caveats prominently noted

### /how-to-get/
- Reality check: not commercially available anywhere
- Pathway 1: Clinical trial enrollment — free, monitored, search instructions
- Pathway 2: Health Canada Special Access Programme — criteria, process, limitations
- Pathway 3: Wait for regulatory approval — estimated 2026-2027 timeline
- Warnings section: unregulated online sellers, compounding pharmacies, purity/safety risks
- Links to Health Canada SAP guidance document

### /safety/
- Common side effects table from Phase 2 (NEJM 2023 citation)
- GI management strategies (dose titration, diet, timing)
- Serious risks: thyroid C-cell tumors (contraindicated in MTC/MEN2), pancreatitis, gallbladder disease, hypoglycemia
- Knowledge gaps: long-term safety >48 weeks, rare events, pregnancy, drug interactions, glucagon-specific risks
- Non-pharmaceutical product warning

### /news/
- 4 articles: TRIUMPH-1 results, Canadian implications, Phase 2 NEJM, TRIUMPH-4 completion
- Updated via daily cron job (9 AM ET) checking Google News RSS

### /waitlist/
- Email capture form for Canadian availability updates
- What subscribers receive: approval milestones, trial openings, data releases
- Privacy commitment, unsubscribe info
- Medical disclaimer

### /fr/ (French homepage)
- Full French translation of homepage content
- Canadian French (fr-CA) medical terminology

### /fr/* (French pages)
- All English pages have French counterparts at /fr/ routes
- Bidirectional hreflang tags on every page
- Language toggle in navigation

---

## Technical Details

- **Framework**: Astro v6.3.5 with SSR (Node adapter)
- **Styling**: Tailwind CSS v4 with custom design tokens
- **Design**: Editorial/journal aesthetic — pure white, ruled-line separators, Merriweather serif headings, one accent blue (#1a56db)
- **SEO**: JSON-LD (Article, FAQ, BreadcrumbList), hreflang, canonical URLs, sitemap auto-generation
- **Analytics**: Google Analytics 4 (G-Y3YM56HD4G)
- **Deployment**: Replit → Google Cloud, Cloudflare DNS
- **Content**: Markdown-based news collection with glob loader

## Key Clinical Data Points

- **Drug**: Retatrutide (LY3437943), Eli Lilly
- **Class**: GIP/GLP-1/glucagon receptor triple agonist
- **Route**: Once-weekly subcutaneous injection
- **Phase 2**: 24.2% mean weight loss at 48 weeks (NEJM 2023, n=338)
- **Phase 3 TRIUMPH-1**: 30.3% mean weight loss (Lilly press release, May 2026)
- **Approval status**: Not approved by Health Canada, FDA, or EMA
- **Canadian access**: Clinical trials only; SAP case-by-case
- **Canadian trial sites**: 9-22 across TRIUMPH trials

## Sources Cited Throughout Site

1. Jastreboff AM, et al. N Engl J Med 2023; 389:514-526. DOI: 10.1056/NEJMoa2301972
2. TRIUMPH-1: NCT05929066
3. TRIUMPH-2: NCT05929079
4. TRIUMPH-OUTCOMES: NCT06383390
5. TRIUMPH-4: NCT05931367
6. TRIUMPH-5: NCT06260722
7. SURMOUNT-1: NCT04184622
8. STEP-1: NCT03548935
9. Eli Lilly investor relations press releases
10. Health Canada Special Access Programme guidance
11. TRIUMPH trial design paper: DOI 10.1111/dom.70209